MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Moisture sensitive medicine. Store in airtight (sealed) MCA. Protect from light. Original packaging may contain desiccant. Mixed results from stability studies but likely supports 5 weeks in sealed MCA when protected from moisture and light.

Provenance

This recommendation is based on 75mg Aspirin Dispersible Tablets (Accord-UK Ltd) and Dispersible Aspirin Tablets BP 75mg (Crescent Pharma Ltd).

Stability Notes

Moisture sensitive medicine. Store in airtight (sealed) MCA. Protect from light. Original packaging may contain desiccant. Mixed results from stability studies but likely supports 5 weeks in sealed MCA when protected from moisture and light.

Provenance

This recommendation is based on 75mg Aspirin Dispersible Tablets (Accord-UK Ltd) and Dispersible Aspirin Tablets BP 75mg (Crescent Pharma Ltd).

Stability Notes

Moisture sensitive medicine. Store in airtight (sealed) MCA. Protect from light. Original packaging may contain desiccant. Mixed results from stability studies but likely supports 5 weeks in sealed MCA when protected from moisture and light.

Provenance

This recommendation is based on 75mg Aspirin Dispersible Tablets (Accord-UK Ltd) and Dispersible Aspirin Tablets BP 75mg (Crescent Pharma Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Nu-Seals 75 gastro-resistant tablets (Alliance Pharmaceuticals Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Nu-Seals 75 gastro-resistant tablets (Alliance Pharmaceuticals Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Nu-Seals 75 gastro-resistant tablets (Alliance Pharmaceuticals Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Nu-Seals 75 gastro-resistant tablets (Alliance Pharmaceuticals Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Nu-Seals 75 gastro-resistant tablets (Alliance Pharmaceuticals Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Nu-Seals 75 gastro-resistant tablets (Alliance Pharmaceuticals Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Nu-Seals 75 gastro-resistant tablets (Alliance Pharmaceuticals Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Nu-Seals 75 gastro-resistant tablets (Alliance Pharmaceuticals Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Nu-Seals 75 gastro-resistant tablets (Alliance Pharmaceuticals Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Nu-Seals 75 gastro-resistant tablets (Alliance Pharmaceuticals Ltd).

Stability Notes

There are no stability notes available for this medicine.
Print this list

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Medicines under this category are not suitable for use in MCAs.
These medicines have not been reviewed by SPS.